PI-RADS第2版与第2.1版对移行区前列腺癌检测的诊断准确性和观察者间一致性
本回顾性研究纳入355例未经活检患者的前列腺MRI,评估5名不同经验放射科医生使用PI-RADS v2和v2.1对移行区病变的观察者间一致性和诊断准确性。结果显示PI-RADS v2.1的观察者间一致性更高(平均加权κ=0.700 vs 0.622),检测移行区前列腺癌和临床显著前列腺癌的AUC均更高(0.866 vs 0.827;0.929 vs 0.899),且读者经验仍影响诊断性能。
要点
- PI-RADS v2.1对移行区病变的观察者间一致性优于v2(平均加权κ=0.700 vs 0.622)。
- PI-RADS v2.1检测移行区临床显著前列腺癌的AUC为0.929,高于v2的0.899。
- 读者经验影响诊断性能,经验最少者检测临床显著前列腺癌的敏感度、特异度和准确率分别为78.0%、89.2%和87.3%。
核心结论
- PI-RADS v2.1对移行区病变的观察者间一致性和诊断准确性均优于PI-RADS v2。
- 读者经验仍影响使用PI-RADS v2.1进行前列腺MRI解读的性能。
研究设计与样本
- 回顾性研究,纳入2017年1月至2020年3月间355例未经活检、前列腺MRI显示移行区病变并接受后续活检的患者。
- 前列腺癌确诊93例(ISUP分级组1为34例,ISUP分级组≥2为59例),非癌性病变262例。
- 5名前列腺MRI经验不同的放射科医生分别使用PI-RADS v2和v2.1对病变评分,两次评分间隔至少4周。
- 采用κ和Kendall W统计评估观察者间一致性,采用ROC曲线分析评估检测移行区前列腺癌和临床显著前列腺癌的性能。
诊断标准与关键数值
- 所有读者间观察者间一致性PI-RADS v2.1高于v2(平均加权κ=0.700 vs 0.622;Kendall W=0.805 vs 0.728;p=.03)。
- 检测移行区前列腺癌的汇总AUC:PI-RADS v2.1为0.866,v2为0.827(p<.001)。
- 检测移行区临床显著前列腺癌的汇总AUC:PI-RADS v2.1为0.929,v2为0.899(p<.001)。
- 检测移行区前列腺癌:PI-RADS v2.1汇总敏感度86.9%、特异度79.4%、准确率75.4%;v2分别为79.4%、71.8%、73.8%。
- 检测移行区临床显著前列腺癌:PI-RADS v2.1汇总敏感度84.8%、特异度90.9%、准确率89.9%;v2分别为81.4%、89.9%、88.5%。
临床应用与阅片要点
- PI-RADS v2.1对移行区前列腺癌的诊断比v2更准确、可重复性更好。
- 经验最少的读者(读者1)检测临床显著前列腺癌的敏感度、特异度和准确率最低(78.0%、89.2%、87.3%)。
- 经验最多的读者(读者5)检测临床显著前列腺癌的敏感度、特异度和准确率最高(88.1%、92.9%、92.1%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. PI-RADS version 2.1 (v2.1) introduced a number of key changes to the assessment of transition zone (TZ) lesions. OBJECTIVE. The purpose of this study was to evaluate interobserver agreement and diagnostic accuracy for detecting TZ prostate cancer (PCa) and clinically significant PCa (csPCa) by use of PI-RADS v2 and PI-RADS v2.1 among radiologists with different levels of experience. METHODS. This retrospective study included 355 biopsy-naïve patients who from January 2017 to March 2020 underwent prostate MRI that showed a TZ lesion and underwent subsequent biopsy. PCa was diagnosed in 93 patients (International Society of Urological Pathology [ISUP] grade group 1, n = 34; ISUP grade group ≥ 2, n = 59) and non-cancerous lesions in 262 patients. Five radiologists with varying experience in prostate MRI scored lesions using PI-RADS v2 and PI-RADS v2.1 in sessions separated by at least 4 weeks. Interobserver agreement was evaluated with kappa and Kendall W statistics. ROC curve analysis was used to evaluate performance in detection of TZ PCa and csPCa. RESULTS. Interobserver agreement among all readers was higher for PI-RADS v2.1 than for PI-RADS v2 (mean weighted κ = 0.700 vs 0.622; Kendall W = 0.805 vs 0.728; p = .03). The pooled AUC values for detecting TZ PCa and csPCa were higher among all readers using PI-RADS v2.1 (0.866 vs 0.827 for TZ PCa; 0.929 vs 0.899 for TZ csPCa; p < .001). For detecting TZ PCa, the pooled sensitivity, specificity, and accuracy were 86.9%, 79.4%, and 75.4% among all readers for PI-RADS v2.1 compared with 79.4%, 71.8%, and 73.8% for PI-RADS v2. For detecting TZ csPCa, the pooled sensitivity, specificity, and accuracy were 84.8%, 90.9%, and 89.9% among all readers for PI-RADS v2.1 compared with 81.4%, 89.9%, and 88.5% for PI-RADS v2. Reader 1, who had the least experience, had the lowest sensitivity, specificity, and accuracy (78.0%, 89.2%, and 87.3%). Reader 5, who had the most experience, had the highest sensitivity, specificity, and accuracy (88.1%, 92.9%, and 92.1%) in detecting csPCa. CONCLUSION. PI-RADS v2.1 had better interobserver agreement and diagnostic accuracy than PI-RADS v2 for evaluating TZ lesions. Reader experience continues to affect the performance of prostate MRI interpretation with PI-RADS v2.1. CLINICAL IMPACT. PI-RADS v2.1 is more accurate and reproducible than PI-RADS v2 for the diagnosis of TZ PCa.
引用
- Wei CG, Zhang YY, Pan P, et al. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers. AJR Am J Roentgenol. 2021. PMID: 32755220. doi:10.2214/AJR.20.23883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。